Administrative/Clinical Trials Core

行政/临床试验核心

• 批准号: 7290718
• 负责人: Kirby I. Bland
• 金额: $ 28.59万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7290718
• 关键词: 90Y-DOTA-Biotin; Accounting; Achievement; Activation Date; Address; Adenocarcinoma; Adenovirus Vector; Adenoviruses; Adjuvant; Administrative Personnel; Administrator; Advertisements; Advisory Committees; Advocacy; Advocate; African; African American; Age; Alabama; Amendment; American; American Association of Cancer Research; American Cancer Society; American College of Surgeons; American College of Surgeons Oncology Group; American Society of Clinical Oncology; Animal Experiments; Animal Model; Antibodies; Apoptosis; Appendix; Applications Grants; Appointment; Area; Arts; Aspirate substance; Atlases; Atypia; Avastin; Award; Awareness; Back; Baltimore; Basic Science; Behavioral Research; Belief; Benchmarking; Benign; Bibliography; Biochemistry; Biodistribution; Bioinformatics; Biological; Biological Assay; Biological Markers; Biology; Biomedical Research; Biometry; Blood; Blood specimen; Bone Marrow Neoplasms; Boston; Brain; Breast; Breast Cancer Cell; Breast Cancer Detection; Breast Cancer Prevention; Breast Carcinoma; Breast Diseases; Breast Feeding; Budgets; Businesses; Cancer Center; Cancer Center Support Grant; Cancer Patient; Cancer Survivor; Cancer Therapy Evaluation Program; Cancer and Leukemia Group B; Cancer cell line; Capecitabine/Paclitaxel; Carboplatin; Caring; Categories; Cell Cycle Checkpoint; Cell surface; Cells; Cellular Morphology; Cellular biology; Center Core Grants; Centers of Research Excellence; Cetuximab; Chairperson; Characteristics; Chemoprevention; Chemopreventive Agent; Chemotherapy-Oncologic Procedure; Child; Chimeric Proteins; Cities; Classification; Clinic; Clinical; Clinical Chemoprevention; Clinical Data; Clinical Investigator; Clinical Protocols; Clinical Research; Clinical Trials; Clinical trial protocol document; Closure; Collaborations; Collection; Combined Modality Therapy; Commit; Communication; Communities; Community Health; Complex; Comprehension; Comprehensive Cancer Center; Computer software; Computers; Conduct Clinical Trials; Confidentiality of Patient Information; Conflict of Interest; Consent Forms; Consultations; Consumer Advocates in Research and Related Activities; Controlled Study; Core Facility; Counseling; County; Critiques; Cyclic AMP; Cyclophosphamide; Cytology; Cytotoxic T-Lymphocytes; DOTA-biotin; Daily; Dana-Farber Cancer Institute; Data; Data Analyses; Data Collection; Databases; Decision Making; Dependovirus; Depth; Development; Devices; Diagnosis; Direct Costs; Discipline; Disease; Disease Progression; Disease remission; Disease-Free Survival; Disorder by Site; Doctor of Medicine; Doctor of Philosophy; Dose; Dose-Limiting; Doxorubicin; Drug Kinetics; Drug resistance; Ductal; EGF gene; ERBB2 gene; Eastern Cooperative Oncology Group; Education; Educational Curriculum; Educational Materials; Educational workshop; Eligibility Determination; Emotional Stress; Employment; Enrollment; Ensure; Environment; Epidemiology; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Epithelial Cells; Epithelium; Equilibrium; Equipment; Erlotinib; Estradiol; Estrogen Antagonists; Estrogen receptor positive; Estrogens; Evaluation; Excision; Expenditure; Faculty; Family; Feedback; Fellowship; Florida; Foundations; Frequencies; Friends; Functional disorder; Funding; Funding Agency; Future; G-Protein-Coupled Receptors; GTP-Binding Proteins; Gastrointestinal tract structure; Gender; Gene Expression; General Practices; Generations; Genes; Genetic; Genistein; Goals; Government; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; Guanosine Monophosphate; Guidelines; Head; Health; Health Insurance Portability and Accountability Act; Health Personnel; Health Services; Hematology; Heparin Binding; High Risk Woman; Histologic; Hormonal; Hormonal Change; Hormone Receptor; Hormones; Hour; Howard Temin Award; Human; Human Biology; Human Resources; Image; Imaging Techniques; Immune; Immune response; Immunology; Immunotherapy; In Situ; Incidence; Individual; Industry; Industry Collaborators; Infant; Information Systems; Informed Consent; Institutes; Institution; Intellectual Property; Internal Medicine; Intervention; Intervention Trial; Interview; Intestinal Cancer; Intravenous; Invasive; Investigation; Iowa; Irrigation; Journals; K-Series Research Career Programs; Kansas; Knowledge; Label; Laboratories; Laboratory Research; Language; Lasers; Leadership; Left; Letrozole; Letters; Life; Link; Liquid substance; Lobular Carcinoma; Local Area Networks; Localized; London; Los Angeles; Louisiana; Magnetic Resonance Imaging; Mails; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of pancreas; Mammary Gland Parenchyma; Mammography; Management Audit; Manuscripts; Marrow; Maximum Tolerated Dose; Measurement; Measures; Mediating; Medical; Medical Oncologist; Medical Oncology; Medical center; Medicine; Memorial Sloan-Kettering Cancer Center; Menopause; Mentors; Mentorship; Meta-Analysis; Metabolic; Methodology; Methods; Methylation; Michigan; Microdissection; Minority; Mission; Molecular; Molecular Genetics; Molecular Profiling; Molecular and Cellular Biology; Monitor; Monitoring Clinical Trials; Monoclonal Antibodies; Monoclonal Antibody CC49; Mus; NCI Director' s Consumer Liaison Group; Names; National Cancer Advisory Board; National Cancer Institute; National Surgical Adjuvant Breast and Bowel Project; Nature; Needles; Neoadjuvant Therapy; Neoplasm Metastasis; Network-based; New York; Newly Diagnosed; Nipples; Normal tissue morphology; North Carolina; Notification; Nuclear; Numbers; Nurses; Nursing Research; Nutritional; Oncogenes; Online Systems; Operative Surgical Procedures; Outcome; Ovary; PCNA gene; Paclitaxel; Pancreas; Participant; Pathologic; Pathology; Pathway interactions; Patient Care; Patient Education; Patient Recruitments; Patient advocacy; Patient currently pregnant; Patients; Pattern; Peer Review; Peer Review Grants; Performance; Personal Computers; Personal Satisfaction; Personnel Recruitments; Persons; Pharmacists; Pharmacologic Substance; Pharmacy facility; Phase; Phase I Clinical Trials; Phase I/II Trial; Phase II Clinical Trials; Phase III Clinical Trials; Phenotype; Philadelphia; Physical Examination; Physician Executives; Physicians; Physiology; Plasma; Plasmid Cloning Vector; Pliability; Policies; Polynucleotide Vaccines; Population; Populations at Risk; Positioning Attribute; Positron-Emission Tomography; Postmenopause; Preparation; Prevention; Prevention Research; Prevention intervention; Principal Investigator; Prior Chemotherapy; Problem Solving; Procedures; Process; Production; Productivity; Professional counselor; Program Description; Program Development; Progress Reports; Proliferative Index; Protein Overexpression; Protein Subunits; Proteins; Proto-Oncogene Proteins c-akt; Protocols documentation; Public Health Schools; Publications; Publishing; Purpose; Pyrroloiminoquinones; Qualifying; Quality Control; Radiation; Radioactive; Radioimmunotherapy; Radioisotopes; Radiolabeled; Radiology Specialty; Rate; Reagent; Recommendation; Recording of previous events; Records; Recovery; Recruitment Activity; Registered nurse; Registries; Regulation; Reporting; Reproducibility; Reproduction spores; Research; Research Activity; Research Design; Research Ethics Committees; Research Infrastructure; Research Personnel; Research Priority; Research Project Grants; Research Support; Research Training; Residual Tumors; Resistance; Resource Allocation; Resources; Retinoids; Review Committee; Rights; Risk; Role; Rural Population; Safety; Sampling; Schedule; Schools; Science; Scientific Evaluation; Scientist; Score; Screening procedure; Selective Estrogen Receptor Modulators; Seminal; Senior Scientist; Serum; Services; Shock; Signal Pathway; Signal Transduction; Site; Slide; Societies; Solid; Source; Southwest Oncology Group; Specificity; Specimen; Speed; Staging; Strategic Planning; Streptavidin; Structure; Study Section; Study Subject; Suggestion; Supervision; Support Groups; Surgeon; Surgical Oncologist; Surgical Oncology; Surgical Pathology; Surrogate Endpoint; Surrogate Markers; Survivors; Susan G Komen Breast Cancer Foundation; System; T-Lymphocyte; TAG-72 Antigen; TNF receptor-associated factor 4; TNFRSF5 gene; TP53 gene; TRAF4 gene; Tamoxifen; Techniques; Technology; Teleconferences; Terminology; Testing; Text; Therapeutic; Therapeutic Agents; Therapeutic Intervention; Time; TimeLine; Tissue Banks; Tissue Procurements; Tissue Sample; Tissues; Title; Today; Toxic effect; Toxin; Training; Training Programs; Transactivation; Transfection; Transgenic Organisms; Translational Research; Translations; Trauma; Treatment Protocols; Trust; Tumor Immunity; Tumorigenicity; Tyrosine Kinase Inhibitor; Ultrasonography; Underserved Population; United States; United States Food and Drug Administration; United States National Institutes of Health; Universities; University Hospitals; University of Alabama at Birmingham Cancer Center; Update; Vaccine Therapy; Vaccines; Vascular Endothelial Growth Factors; Virginia; Visit; Week; Woman; Women' s Group; Women' s Health; Work; Writing; abstracting; angiogenesis; antibody conjugate; anticancer research; base; bevacizumab; breast cancer diagnosis; breast surgery; cancer care; cancer diagnosis; cancer prevention; cancer research center director; cancer therapy; carcinogenesis; career; caucasian American; chemotherapy; college; community organizations; computer network; conditionally replicative adenovirus; cooperative study; cost effective; data acquisition; data management; day; death receptor-4; design; desire; dosimetry; driving force; ductal breast carcinoma; experience; feeding; fight against; fighting; follow-up; gastrointestinal; gene therapy; hormone therapy; human TNFRSF10A protein; human subject; immune function; immunogenicity; immunopathology; improved; injured; innovation; interest; intravenous administration; investigator training; malignant breast neoplasm; medical schools; medically underserved population; member; men; minority health; minority subjects; mortality; mouse model; mullerian-inhibiting hormone; multidisciplinary; mutant; neoplastic cell; novel; novel therapeutics; oncology; organizational structure; outcome forecast; outreach program; patient safety; peer; pilot trial; post-doctoral training; pre-clinical; preclinical study; prenatal; professor; prognostic; programs; promoter; protein expression; protocol development; psychologic; quality assurance; racial and ethnic; radiotracer; receptor; research clinical testing; research study; resistance mechanism; response; restoration; smoothened signaling pathway; socioeconomics; statistics; success; survivin; symposium; therapeutic target; time interval; tissue resource; tool; translational study; tumor; tumor growth; tumor progression; vector; vector vaccine; volunteer

The Administrative/Clinical Trials Core (Core A) is responsible for the administrative support of all DAB Breast SPORE Projects, Cores and Programs, including planning and monitoring of scientific activities, providing scientific direction, ensuring a translational research emphasis, and integrating the Projects, Cores and Programs, including collaborations with other Breast SPORES.The Administrative/Clinical Trials Core provides fiscal oversight including 1) employment of key personnel to ensure cost effective and efficient use of resources and 2) utilization of SPORE flexibility to reallocate funds depending on the degree to which the individual Projects and Cores of the UAB Breast SPORE are successful in meeting their performance benchmarks, which allows the Administrative/Clinical Trials Core to take advantage of new scientific opportunities as well as to remedy deficiencies. The Administrative/Clinical Trials Core provides a vital link between investigators and the UAB Breast SPORE internal and external advisors, as well as NCI program staff, and assumes responsibility for the preparation of all required reports and assurances. An important component of the Administrative/Clinical Trials Core is its oversight of UAB Breast SPORE human clinical trials, which provides for enhanced interactions between the UAB Breast SPORE and the UAB Comprehensive Cancer Center (UABCCC). In regards to the conduct of UAB Breast SPORE human clinical trials, the goals of the Administrative/Clinical Trials Core are to: 1) provide optimal support for human clinical trials; 2) provide patients access to interventions/therapies developed by UAB Breast SPORE investigators; 3) enhance interactions between UAB Breast SPORE basic and clinical investigators; and 4) provide for enhancement and coordination of the resources available through the UABCCC Clinical Trials Shared Facility for utilization by UAB Breast SPORE investigators. Currently, the Breast SPORE has 12 clinical trials generated by SPORE projects, developmental projects or inter-SPORE collaborations. The Administrative/Clinical Trials Core also manages a registered UAB Breast SPORE website and contributes to the Cancer Center Magazine, which serves the UAB community and the friends and supporters of the UABCCC. The Administrative/Clinical Trials Core supports all of the SPORE Projects with planning, monitoring and the achievement of the scientific objectives of each SPORE Project/Core facility.

行政/临床试验核心（核心A）负责所有DAB的行政支持 乳腺孢子项目，核心和计划，包括计划和监测科学活动， 提供科学方向，确保转化研究重点并整合项目， 核心和程序，包括与其他乳腺孢子的合作。行政/临床试验 核心提供财政监督，包括1）雇用关键人员以确保成本效益和 有效利用资源和2）利用孢子的灵活性来重新分配资金，具体取决于该学位 UAB乳腺孢子的各个项目和核心成功地与之相遇 性能基准，该基准允许行政/临床试验核心可以利用新的优势 科学机会以及补救缺陷。行政/临床试验核心提供了 研究人员与UAB乳腺孢子内部和外部顾问以及NCI之间的重要联系 计划人员，并负责准备所有必需的报告和保证。 行政/临床试验核心的重要组成部分是其对UAB乳腺孢子的监督 人类临床试验，可增强UAB乳腺孢子与 UAB综合癌症中心（UABCCC）。关于UAB乳腺孢子人的行为 临床试验，行政/临床试验核心的目标是：1）为 人类临床试验； 2）使患者获得UAB乳房开发的干预措施/疗法 孢子调查员； 3）增强UAB乳腺孢子基本与临床之间的相互作用 调查人员； 4）提供通过该资源的增强和协调 UABCCC临床试验共享UAB乳腺孢子研究人员利用的设施。目前， 乳腺孢子有12项由孢子项目，发育项目或孢子间产生的临床试验 协作。 行政/临床试验核心还管理着注册的UAB乳腺孢子网站和 为癌症中心杂志做出了贡献，该杂志为UAB社区和朋友提供服务 UABCCC的支持者。 行政/临床试验核心通过计划，监测和 实现每个孢子项目/核心设施的科学目标。